small nucleolar RNA, H/ACA box 80AGenealiases: ACA67 · SNORA80
Q-omics provides the consensus-scored SNORA80A profile across patient tissues and cancer cell-line models. SNORA80A expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, SNORA80A is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, SNORA80A RNA expression shows 5,672 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight OV, HNSC, and LUAD as cancer lineages where SNORA80A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA80A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA80A survival associations across molecular data types. SNORA80A RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA80A RNA expression–survival associations across cancer types. High SNORA80A expression shows unfavorable associations in OV, ACC, DLBC, THCA and READ, but favorable associations in KIRP. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for SNORA80A RNA expression.
This table summarizes SNORA80A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA80A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA80A shows lower tumor expression in ESCA and BLCA and higher tumor expression in HNSC, LUAD, BRCA and LUSC. The HNSC box plot shows higher SNORA80A RNA expression in tumor versus normal tissue (log2 FC = +0.221, t-test p < 0.001).
This table shows molecular features associated with SNORA80A in patient tissues and cancer cell lines. In patient samples, SNORA80A shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
